4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

LILLE, France & PARIS--(BUSINESS WIRE)--Aug 4, 2026--

4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoarthritis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803530661/en/

INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial conducted across Europe, the United States and Canada. A total of 129 patients with symptomatic knee osteoarthritis associated with contrast enhanced-MRI-confirmed synovitis were randomized to receive a single intra-articular injection of either 4P004 (2 mg) or placebo, followed by a three-month evaluation period. The study population was selected based on the presence of synovitis rather than obesity status. This phenotype-driven strategy is intended to focus development on patients with a biological feature associated with a higher risk of osteoarthritis progression.

Completion of enrollment marks a major operational and strategic milestone for the program, transitioning the study into patient follow-up and preparation for clinical data readout.

Unlike conventional osteoarthritis studies that primarily assess symptomatic improvement, INFLAM MOTION was designed to go beyond the evaluation of pain relief by integrating contrast-enhanced magnetic resonance imaging (CE-MRI) to assess changes in synovial tissue thickening and inflammation. The study will investigate whether modulation of synovitis is associated with clinical benefit and with an objective biological response in a disease pathway linked to structural progression and future knee replacement. It is expected to generate one of the most comprehensive datasets to date exploring the relationship between symptoms, imaging biomarkers, and inflammatory biology following local GLP-1 receptor activation.

“Completion of enrollment represents an important milestone not only for the development of 4P004 but also for the broader understanding of inflammatory knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer of 4Moving Biotech. “Increasing evidence indicates that synovial inflammation is a major driver of pain and identifies a phenotype associated with structural progression and a greater likelihood of future knee replacement. By acting directly within the joint, 4P004 has been designed not simply to provide symptomatic relief, but to selectively modulate this progression-associated inflammatory pathway, while minimizing systemic exposure. For the first time, INFLAM MOTION will allow us to evaluate whether local GLP-1 receptor activation can translate into a coherent clinical and biological response, combining symptomatic improvement with objective imaging evidence of reduced synovial tissue thickening and inflammation.”

The primary endpoint of the study is the reduction in knee pain at Week 4. Key secondary endpoints include changes in synovial tissue thickness and overall synovitis burden assessed by contrast-enhanced MRI, knee pain at Week 12, imaging biomarkers, and circulating biomarkers associated with osteoarthritis progression.

Beyond evaluating clinical efficacy, INFLAM MOTION is expected to provide important translational insights into the relationship between synovial inflammation, imaging biomarkers and patient outcomes. By studying a synovitis-defined population, the trial is intended to determine whether targeting this inflammatory phenotype may provide a basis for an approach extending beyond symptom control. These data are intended to inform patient selection, endpoint strategy and biomarker integration for the subsequent Phase 2b study, supporting the development of a differentiated regulatory package built upon both clinical benefit and objective evidence of biological activity relevant to potential disease modification.

“Completing enrollment marks the transition from operational execution to clinical value creation,” said Luc Boblet, Chief Executive Officer of 4Moving Biotech. “Over the coming months, INFLAM MOTION is expected to generate a robust clinical dataset assembled around local GLP-1 therapy in osteoarthritis, integrating patient-reported outcomes, advanced imaging and molecular biomarkers. The value of this study lies in determining whether local GLP-1 therapy can combine symptom improvement with measurable modulation of synovitis, an inflammatory feature associated with disease progression. We believe these data will not only guide the next stage of clinical development but also contribute to the growing scientific momentum supporting inflammation as a therapeutic target for altering the course of osteoarthritis, rather than solely managing its symptoms. We look forward to sharing topline results before the end of the year.”

Patient follow-up is ongoing. Topline results are expected by the end of December 2026. The results are expected to inform the design of the subsequent Phase 2b clinical trial, which will further evaluate both clinical benefit and the disease-modifying potential of 4P004 in patients with the synovitis-associated inflammatory phenotype, and contribute to future regulatory interactions supporting the path forward of 4P004 toward market approval.

About 4MB
Incorporated in mid-2020 as a spin-off of 4P-Pharma, 4MB is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need in osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website:https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech

The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee osteoarthritis

TOKYO (AP) — Asian shares were mixed on Tuesday following a rally on Wall Street that was helped by easing oil prices.

Regional investors were still weighing the impact from last week's joint U.S.-Japan currency intervention, analysts said.

Japan's benchmark Nikkei 225 slipped 0.3% to 63,585.58, as the U.S. dollar inched up to 157.51 Japanese yen from 157.18 yen. The euro cost $1.1511, little changed from $1.1514. The dollar was trading at 160-yen levels before regulators stepped in to boost the yen's value after it fell to nearly 40-year lows.

Some analysts said the effectiveness of such an intervention remains uncertain as it doesn't address the fundamental economic reasons behind the currency fluctuations, including inflation, interest rates and the relative strengths of the economies.

“A U.S.-backed operation carries far more signaling weight than Tokyo acting alone, and the pledge of further action will give speculators pause. But any U.S. contribution will probably be constrained by size,” a report by BMI, a unit of Fitch Solutions, said.

Matthew Ryan, head of market strategy at global financial services firm Ebury, noted the latest effort could have some impact because it appears to signal a real change in monetary policy rather than just a one-time defensive move.

“This is an historic and meaningful development for the yen, which materially improves confidence in our mildly bullish call for the currency,” he said.

South Korea's Kospi sank 1.3% to 6,174.72. Australia's S&P/ASX 200 added 1.2% to 9,129.00. Hong Kong's Hang Seng fell 0.5% to 25,881.99, while the Shanghai Composite gained 0.2% to 3,802.61.

Markets remain unsettled by swings for stocks of companies that make computer chips. They’ve been veering up and down for weeks on worries about whether their surging revenues because of the artificial-intelligence boom are sustainable.

On Wall Street, share prices rallied Monday after easing oil prices helped calm worries over inflation. The S&P 500 jumped 1.5% and is just 0.1% below its record set earlier this summer.

The Dow Jones Industrial Average, which measures a narrower slice of the U.S. stock market, climbed 693 points or 1.3% to an all-time high, while the Nasdaq composite leaped 2.1%.

In energy trading in Asia early Tuesday, benchmark U.S. crude gained 84 cents to $81.18 a barrel. Brent crude, the international standard, jumped $1.15 to $84.92 a barrel.

A day earlier, oil prices dropped more than 5% after U.S. President Donald Trump said over the weekend that he had decided to hold off on new strikes against Iran at the urging of allies in the region.

Brent’s price careened between $72 and $102 last month as worries rose and fell over the war in Iran and when oil tankers would be allowed to freely exit the Persian Gulf again to deliver crude to customers worldwide.

The yield on the 10-year Treasury sank to 4.68% from 4.75% late Friday. It remains well above its 3.97% level from before the war with Iran.

AP Business Writer Stan Choe contributed to this report.

Yuri Kageyama is on Threads: https://www.threads.com/@yurikageyama

A trader works on the floor of the New York Stock Exchange, Thursday, July 30, 2026, in New York. (AP Photo/Yuki Iwamura)

Currency traders watch monitors near a screen showing the Korea Composite Stock Price Index (KOSPI) and the foreign exchange rate between U.S. dollar and South Korean won at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Tuesday, Aug. 4, 2026. (AP Photo/Ahn Young-joon)

Currency traders work at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Tuesday, Aug. 4, 2026. (AP Photo/Ahn Young-joon)